Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01481779 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants With Type 1 Diabetes Mellitus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
NCT01481779 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 455 participants.
The verdict
NCT01481779, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
Study Summary
The purpose of this study is: * To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment. * To compare the rate of night-time low blood sugar episodes on LY2605541 with insulin glargine during 78 weeks of treatment. * To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 78 weeks of treatment. * To compare the rate of hypoglycemia episodes on LY2605541 with insulin glargine during 78 weeks of treatment.
Interventions
- DRUG Glargine
- DRUG Insulin Lispro
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01481779
The ClinicalTrials.gov registry entry for NCT01481779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glargine is the first listed.
NCT01481779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01481779 about?
NCT01481779 is a clinical study titled "A Study in Participants With Type 1 Diabetes Mellitus". The purpose of this study is: * To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment. * To compare the rate of night-time low blood sugar episodes on LY2605541 with insulin glargine during 78 weeks of treatment. * To compare the number of participants on...
What is the current status of trial NCT01481779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2012-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01481779?
The interventions under investigation include: Glargine (DRUG), Insulin Lispro (DRUG), LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01481779?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.